PriceTargets.com logo

Motus GI - MOTS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 283.33 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.00 As of 10/6/2022 02:16 PM ET
▲ +1.12 (59.57%)

This chart shows the closing price for MOTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Motus GI Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MOTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MOTS

Analyst Price Target is $11.50
▲ +283.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Motus GI in the last 3 months. The average price target is $11.50, with a high forecast of $12.00 and a low forecast of $11.00. The average price target represents a 283.33% upside from the last price of $3.00.

This chart shows the closing price for MOTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Motus GI. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022HC WainwrightLower TargetBuy$20.00 ➝ $11.00Low
8/11/2022Alliance Global PartnersLower Target$24.00 ➝ $12.00Low
5/16/2022HC WainwrightLower TargetNA$40.00 ➝ $30.00High
3/22/2022Colliers SecuritiesReiterated RatingBuyLow
1/26/2022Alliance Global PartnersLower Target$35.00 ➝ $28.00High
11/15/2021HC WainwrightReiterated RatingBuy$40.00Medium
9/9/2021HC WainwrightReiterated RatingBuy$40.00Low
8/12/2021Piper SandlerLower TargetPositive ➝ Overweight$50.00 ➝ $30.00High
6/4/2021HC WainwrightReiterated RatingBuy$40.00High
5/14/2021Alliance Global PartnersLower TargetBuy$50.00 ➝ $41.00Medium
11/16/2020HC WainwrightLower TargetBuy$60.00 ➝ $40.00High
11/12/2020Piper SandlerLower TargetOverweight$60.00 ➝ $50.00High
9/9/2020Alliance Global PartnersBoost TargetBuy$33.00 ➝ $52.00Medium
8/12/2020Colliers SecuritiesReiterated RatingBuyLow
8/12/2020OppenheimerReiterated RatingBuy$50.00High
6/16/2020HC WainwrightReiterated RatingBuy$60.00High
5/14/2020OppenheimerInitiated CoverageBuy$60.00High
4/21/2020HC WainwrightInitiated CoverageBuy$60.00Medium
3/31/2020Piper SandlerLower Target$80.00 ➝ $60.00Low
9/26/2019Dougherty & CoSet TargetBuy$140.00High
5/10/2019Piper Jaffray CompaniesLower Target$160.00 ➝ $120.00Low
3/28/2019OppenheimerSet TargetBuy$200.00Medium
11/26/2018OppenheimerSet TargetBuy$200.00High
9/25/2018OppenheimerReiterated RatingBuyMedium
8/30/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$290.00High
8/28/2018Dougherty & CoInitiated CoverageBuy ➝ Buy$160.00High
8/15/2018OppenheimerSet TargetBuy$200.00Low
8/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$160.00Low
7/13/2018OppenheimerSet TargetBuy$200.00High
5/31/2018EuroPacific CanadaInitiated CoverageBuy$240.00High
3/12/2018OppenheimerInitiated CoverageOutperform$140.00High
3/11/2018Piper Jaffray CompaniesInitiated CoverageOverweight$140.00High
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Motus GI logo
Motus GI Holdings, Inc., a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
Read More

Today's Range

Now: $3.00
Low: $2.06
High: $3.16

50 Day Range

MA: $3.34
Low: $1.88
High: $4.80

52 Week Range

Now: $3.00
Low: $1.72
High: $16.00

Volume

408,702 shs

Average Volume

1,358,460 shs

Market Capitalization

$9 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Motus GI?

The following sell-side analysts have issued stock ratings on Motus GI in the last year: Alliance Global Partners, Colliers Securities, and HC Wainwright.
View the latest analyst ratings for MOTS.

What is the current price target for Motus GI?

2 Wall Street analysts have set twelve-month price targets for Motus GI in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 283.3%. Alliance Global Partners has the highest price target set, predicting MOTS will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Motus GI in the next year.
View the latest price targets for MOTS.

What is the current consensus analyst rating for Motus GI?

Motus GI currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MOTS will outperform the market and that investors should add to their positions of Motus GI.
View the latest ratings for MOTS.

What other companies compete with Motus GI?

Other companies that are similar to Motus GI include InVivo Therapeutics, Sintx Technologies, Ra Medical Systems, GBS and NEXGEL. Learn More about companies similar to Motus GI.

How do I contact Motus GI's investor relations team?

Motus GI's physical mailing address is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. The company's listed phone number is (954) 541-8000 and its investor relations email address is [email protected] The official website for Motus GI is www.motusgi.com. Learn More about contacing Motus GI investor relations.